<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670656</url>
  </required_header>
  <id_info>
    <org_study_id>P08257</org_study_id>
    <secondary_id>2012-002449-40</secondary_id>
    <secondary_id>MK-8175A/MK-8342B-057</secondary_id>
    <nct_id>NCT01670656</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)</brief_title>
  <official_title>A Multicenter, Randomized, Partially Blinded, Placebo-controlled Clinical Trial to Evaluate the Effect on Primary Dysmenorrhea of Vaginal Rings With an Average Daily Release of 700 μg Nomegestrol Acetate (NOMAC) and 300 μg Estradiol (E2), or 900 μg Nomegestrol Acetate (NOMAC) and 300 μg Estradiol (E2), or 100 μg Etonogestrel (ENG) and 300 μg E2, or 125 μg Etonogestrel (ENG) and 300 μg E2. Protocol MK-8175A/MK-8342B 057 (Abbreviated as P057), Also Known as SCH900121/SCH900432 08257 (Abbreviated as P08257)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates four vaginal ring groups with respect to relief of primary
      dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant
      treatment efficacy in relief of primary dysmenorrhea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study investigates four vaginal ring groups with respect to relief of primary
      dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant
      treatment efficacy in relief of primary dysmenorrhea. The intake of ibuprofen rescue
      medication and the impact on daily life is investigated: change from baseline data of these
      two variables will be compared between each of the four active ring groups, separately, and
      the placebo ring group. Furthermore, the study assesses the measurement characteristics and
      psychometric properties of a newly developed Dysmenorrhea Daily Dairy. Vaginal bleeding
      pattern and general safety and tolerability will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Menstrual Cramping Pain Score</measure>
    <time_frame>Baseline to End of Cycle 2 (Day 56)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Total Impact Score</measure>
    <time_frame>Baseline to End of Cycle 2 (Day 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Ibuprofen Tablets</measure>
    <time_frame>Baseline to End of Cycle 2 (Day 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Days of Ibuprofen Intake</measure>
    <time_frame>Baseline to End of Cycle 2 (Day 56)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">439</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>700 μg NOMAC/300 μg E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 μg NOMAC/300 μg E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 μg ENG/300 μg E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>125 μg ENG/300 μg E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)</intervention_name>
    <description>Either 700 or 900 μg NOMAC and 300 μg E2 intravaginal ring for two 28-day cycles</description>
    <arm_group_label>700 μg NOMAC/300 μg E2</arm_group_label>
    <arm_group_label>900 μg NOMAC/300 μg E2</arm_group_label>
    <other_name>SCH900121</other_name>
    <other_name>MK-8175A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel containing contraceptive vaginal ring (ENG-CVR)</intervention_name>
    <description>Either 100 or 125 μg ENG and 300 μg E2, intravaginally for two 28-day cycles</description>
    <arm_group_label>100 μg ENG/300 μg E2</arm_group_label>
    <arm_group_label>125 μg ENG/300 μg E2</arm_group_label>
    <other_name>SCH900432</other_name>
    <other_name>MK-8342B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match vaginal ring, intravaginally for two 28-day cycles</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)</description>
    <arm_group_label>700 μg NOMAC/300 μg E2</arm_group_label>
    <arm_group_label>900 μg NOMAC/300 μg E2</arm_group_label>
    <arm_group_label>100 μg ENG/300 μg E2</arm_group_label>
    <arm_group_label>125 μg ENG/300 μg E2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Motrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥18 and ≤35

          -  Established diagnosis of primary dysmenorrhea

          -  If of child-bearing potential must agree to use condoms for contraception during the
             entire screening period, treatment period, and post-treatment period until the final
             study visit, unless she or her partner are surgically sterilized

          -  Agree to stop using hormonal contraceptive (combined or progestin-only), or a non
             hormonal intrauterine device (IUD)

          -  Regular menstrual cycles ranging from 24 to 35 days in length

        Exclusion Criteria:

          -  Any of the following contraindications to the use of contraceptive steroids
             including: presence or a history of venous or arterial thrombotic/thromboembolic
             events or cerebrovascular accident (stroke, history of migraine with focal
             neurological symptoms, diabetes mellitus with vascular involvement, severe or
             multiple risk factor(s) for venous or arterial thrombosis, severe dyslipoproteinemia,
             severe hypertension, pancreatitis or a history thereof if associated with severe
             hypertriglyceridaemia, presence or history of severe hepatic (liver) disease,
             including benign or malignant tumors, known or suspected sex steroid-influenced
             malignancies, and/or undiagnosed vaginal bleeding

          -  Pregnant or breastfeeding

          -  Secondary dysmenorrhea

          -  Has not had spontaneous menstruation following a delivery or abortion

          -  Participated in an investigational drug study within 30 days

          -  History of malignancy ≤5 years

          -  Documented abnormal cervical smear result within 6 months

          -  Use of recreational or illicit drugs

          -  Consumes &gt;2 alcoholic drinks per day or &gt;14 alcoholic drinks per week, or engages in
             binge drinking

          -  Allergy/sensitivity to ibuprofen, or any contraindication to its use, or has
             experienced asthma, urticaria, or allergic-type reactions after taking aspirin, or
             other nonsteroidal anti inflammatory drugs

          -  Has been sterilized using a fallopian tube occlusion device

          -  Is receiving, or has received sex hormones for any purpose other than contraception
             within 2 months or injectable hormonal contraception within 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 24, 2015</lastchanged_date>
  <firstreceived_date>August 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
